Acquiring Company
Apimeds Pharmaceuticals US
Acquired Company
FreeT
Description
On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with FreeT Inc. to acquire certain Apitox-related rights. The acquisition was formalized through an amendment that clarifies the consideration to be paid. Apimeds will issue 350,000 shares of common stock and potentially additional payments based on valuation.
Quick answer
Apimeds Pharmaceuticals US is acquiring FreeT, announced November 20, 2026. Apimeds Pharmaceuticals US is based in Matawan, New Jersey, United States.
- How much did Apimeds Pharmaceuticals US pay for FreeT?
- The deal value was not disclosed.
- What does Apimeds Pharmaceuticals US do?
- Apimeds Pharmaceuticals US, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for critical unmet medical needs.
- Where are Apimeds Pharmaceuticals US and FreeT based?
- Apimeds Pharmaceuticals US is based in Matawan, New Jersey, United States. FreeT is based in South Korea.
- Who are the decision-makers at Apimeds Pharmaceuticals US?
- Fundz holds 1 contact at Apimeds Pharmaceuticals US. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Acrivon Therapeutics Acquires Aqilion’s Drug Development Programs (November 6, 2026)
- Nuformix proposes merger with Biovara (November 11, 2026)
- Abeona Therapeutics to Acquire APT-1011 Assets from Ellodi Pharmaceuticals (November 9, 2026)
- BioAdaptives, Inc. to acquire Xycota Biosciences LLC to Expand Biotechnology Portfolio (November 4, 2026)
- Indivior Pharmaceuticals Completes Acquisition of Supernus Pharmaceuticals (November 2, 2026)
- Biossil Labs Inc. Acquires SYN-004 and Related Assets from Theriva Biologics, Inc. (November 2, 2026)
Who to call at Apimeds Pharmaceuticals US, and when
When Apimeds Pharmaceuticals US changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Apimeds Pharmaceuticals US raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Apimeds Pharmaceuticals US, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Apimeds Pharmaceuticals US. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Apimeds Pharmaceuticals US makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired FreeT?
FreeT was acquired by Apimeds Pharmaceuticals US, based in Matawan. The deal was reported on November 21, 2026. Apimeds Pharmaceuticals US, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for critical unmet medical needs. Apimeds Pharmaceuticals US is publicly traded (APUS) and operates in Biotechnology.
When did Apimeds Pharmaceuticals US acquire FreeT?
Apimeds Pharmaceuticals US's acquisition of FreeT was reported on November 21, 2026. On August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with FreeT Inc. to acquire certain Apitox-related rights. The acquisition was formalized through an amendment that clarifies the consideration to be paid. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does FreeT do?
FreeT Inc. is a company organized under the laws of the Republic of Korea. Formerly known as CNP Roen Co., Ltd., it specializes in health and wellness products derived from Apitox. It is privately held, operating in Health Care, and is based in South Korea.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.